Embecta
Embecta Corp. (NASDAQ: EMBC) is a publicly traded medical device company that designs and sells insulin pen needles, syringes, and drug delivery devices to people with diabetes and broader chronic care patients across more than 100 countries, with approximately 2,000 employees and a 100-year insulin delivery heritage.
- Company typePublic
- Founded2022
- HeadquartersFranklin Lakes, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Embecta does
Embecta Corp. (NASDAQ: EMBC) is a publicly traded medical device company headquartered in Parsippany, NJ, that operates a global portfolio of injection and drug delivery devices built around a 100-year legacy in insulin delivery inherited from its 2022 spinoff from Becton Dickinson. The core product line consists of pen needles (Nano 2nd Gen, Nano 4mm, and the Ultra-Fine portfolio) and Ultra-Fine insulin syringes, supplemented by accessories such as alcohol swabs. The company historically derived over 70% of revenue from pen needles and serves more than 30 million people across 100+ countries through healthcare providers, pharmacies, and a direct-to-consumer e-commerce storefront.
Embecta's business model is primarily a hardware sales / medical device model: products are sold through healthcare provider channels, global distributor networks, and retail pharmacy partnerships, with pricing not publicly disclosed and revenue collected via standard medical device reimbursement and pharmacy channels. Following the May 2026 acquisition of UK-based Owen Mumford Holdings Limited (up to £150M including earnout tied to Aidaptus sales through June 2029), the portfolio expanded to include the Aidaptus auto-injector platform — a two-step, single-use device accommodating both 1-mL and 2.25-mL prefilled glass syringes in a single base unit. A March 2026 distribution partnership with NanoTess added the NanoSALV Catalytic wound care gel across 14,000+ Canadian pharmacies, marking the company's first wound care product distribution in Canada and extending the addressable market beyond pure injection devices into adjacent diabetic wound care.
Operationally, the company employs approximately 2,000 people globally and is undergoing a defensive strategic pivot following material deterioration in its core franchise: Q2 fiscal 2026 revenue declined 14.4% YoY to $221.8M with U.S. revenue down 29.4% on pen needle market share loss, full-year 2026 guidance was reduced to $1.015-$1.035B (from prior $1.071-$1.093B), the quarterly dividend was cut 93% from $0.15 to $0.01, and more than 15 securities class action lawsuits have been filed alleging concealment of U.S. pen needle competitive threats. Embecta has announced a review of cost structure and organizational footprint, while pursuing commercial leadership changes (including a new North America president) and offensive moves (Owen Mumford, NanoTess) intended to reposition the company from a diabetes-focused manufacturer into a broader chronic-care drug delivery platform spanning obesity, autoimmune disease, and anaphylaxis.
Embecta firmographics
Firmographics- Name
- Embecta
- Legal name
- Embecta Corp.
- Website
- https://embecta.com
- Company type
- Public
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Embecta Corp. (NASDAQ: EMBC) is a publicly traded medical device company that designs and sells insulin pen needles, syringes, and drug delivery devices to people with diabetes and broader chronic care patients across more than 100 countries, with approximately 2,000 employees and a 100-year insulin delivery heritage.
- Ownership category
- akta.pro rank
Embecta industry classification
Industry- Product category
- Diabetes Care Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Insulin Pen Needles, Syringes & Infusion Sets (Consumables) (HLAHAHAE)
- akta.pro secondary industries
- Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC), Glucagon Rescue Delivery Devices (Auto-Injectors, Nasal) (HLAHAHAK), First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care) (CRADAMAB)
Keywords
Where Embecta is headquartered
LocationHeadquarters
- HQ city
- Franklin Lakes
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Embecta business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Others
Revenue model
- Medical Device Sales: Revenue from sale of pen needles, insulin syringes, safety injection devices, and related diabetes care products
- Drug Delivery Technology: Revenue from auto-injectors and drug delivery devices following Owen Mumford acquisition
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Embecta product offering
Product offeringCore offering
Embecta manufactures and commercializes physical medical devices for insulin delivery, headlined by its Nano and Ultra-Fine pen needles and Ultra-Fine insulin syringes, along with injection accessories such as alcohol swabs. Following the May 2026 acquisition of Owen Mumford, the portfolio expanded to include the Aidaptus auto-injector platform for chronic care applications, and a distribution partnership added NanoSALV catalytic wound care gel in Canada. Products reach more than 30 million people across 100+ countries via healthcare providers, pharmacies, distributors, and an owned e-commerce storefront.
Product overview
Embecta operates as a medical supplies company offering a unified portfolio of diabetes care products centered on insulin injection devices. The core product line includes pen needles (Nano™ 2nd Gen, Nano™ 4mm, and Ultra-Fine™ varieties) and insulin syringes (Ultra-Fine™ Insulin Syringes), supplemented by accessories such as Alcohol Swabs. Following the May 2026 acquisition of Owen Mumford Holdings Limited, the portfolio expanded to include the Aidaptus® auto-injector platform—a two-step, single-use device compatible with 1-mL and 2.25-mL prefilled glass syringes—targeting chronic care markets including obesity, diabetes, autoimmune diseases, and anaphylaxis. A distribution partnership with NanoTess added NanoSALV Catalytic wound care gel for the Canadian market. The company serves more than 30 million people across over 100 countries with approximately 2,000 employees globally, and is pursuing strategic transformation from an insulin delivery leader into a broader medical supplies platform.
Differentiator
Problem solved
Functional benefit
Brands
- Nano: Pen needle product line including Nano 2nd Gen Pen Needles and Nano 4mm Pen Needle
- Ultra-Fine
- Aidaptus
- AutoShield Duo
- NanoSALV
Products and services
- Nano 2nd Gen Pen Needles Second-generation pen needles designed for insulin injection, representing Embecta's updated pen needle technology for people with diabetes.
- Nano 4mm Pen Needle Ultra-thin 4mm pen needle designed to reduce injection pain and improve patient comfort during insulin administration.
- Ultra-Fine Pen Needles Portfolio of pen needles engineered for comfortable and effective insulin delivery, featuring ultra-thin needle technology.
- Ultra-Fine Insulin Syringes Insulin syringes designed for accurate insulin measurement and injection, available in multiple needle lengths and barrel sizes to meet varying patient needs.
- Alcohol Swabs Accessory product for injection preparation, designed to sanitize the injection site prior to insulin administration.
- Aidaptus Auto-Injector Platform A two-step, single-use auto-injector platform capable of accommodating both 1-mL and 2.25-mL prefilled glass syringes in the same base device, acquired via Owen Mumford and targeting chronic care therapy areas including obesity, autoimmune diseases, and anaphylaxis.
- NanoSALV Catalytic Wound Care Gel Wound care product distributed through a partnership with Calgary-based NanoTess, designed as an early intervention and remedial treatment for diabetic foot ulcers, venous leg ulcers, and hard-to-heal wounds.
Quantifiable outcome
- Serving more than 30 million people in over 100 countries
Companies that use Embecta
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Embecta technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Embecta partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Owen Mumford Holdings LimitedcoreEmbecta acquired Owen Mumford Holdings Limited, a UK-based medical device and drug delivery technology manufacturer, for £100 million upfront plus up to £50 million in performance-based payments tied to Aidaptus auto-injector sales through June 2029. The acquisition accelerates Embecta's strategic transformation from a diabetes-focused company into a broader medical supplies company serving chronic care markets including obesity, diabetes, autoimmune diseases, and anaphylaxis. Founded in 1952 and headquartered in Oxfordshire, UK, Owen Mumford developed healthcare devices and drug delivery technologies for over 70 years.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Embecta competitors and assessment
Company assessmentBroad incumbents
- Medtronic (Diabetes division): Major diabetes device player selling MiniMed insulin pumps and AID systems. A broad incumbent in the diabetes care technology ecosystem that competes with Embecta's insulin delivery consumables via pump substitution.
- Novo Nordisk: Global leader in insulin and GLP-1 therapies (Ozempic, Wegovy) whose pen delivery systems both drive and threaten Embecta's pen needle business. Operates broadly in diabetes care with overlapping device ecosystem influence.
Direct peers
- Ypsomed: Swiss manufacturer of pen needles, insulin injection systems, and auto-injectors (YpsoMate) serving diabetes and chronic care pharma—directly competitive with Embecta's pen needle and Aidaptus auto-injector portfolios.
- Stevanato Group: Italy-based drug delivery device manufacturer offering pen injectors, auto-injectors, and prefilled syringe systems to global pharma—competing head-to-head with Embecta's newly acquired Owen Mumford capabilities.
- West Pharmaceutical Services: Global leader in primary packaging and drug delivery components, including auto-injector platforms (SmartDose) and injectable components for insulin and GLP-1 therapies—a peer in the device platform space Embecta targets via Aidaptus.
- Tandem Diabetes Care: Designer and manufacturer of insulin pumps and automated insulin delivery (AID) systems integrating with CGMs—directly competitive with Embecta's pen needle franchise as insulin delivery shifts toward automated systems.
- SHL Medical: Leading independent developer and manufacturer of auto-injectors used by pharma sponsors for chronic care biologics—directly overlapping with Embecta's Aidaptus platform and drug delivery ambitions post-Owen Mumford.
- Insulet: Maker of the Omnipod tubeless insulin pump, which competes for the same diabetes patients whose insulin delivery Embecta's pen needles serve. Insulet is a key substitute product driving Embecta's recent pen needle share loss.
- Becton Dickinson (BD): Embecta's former parent and original developer of its diabetes care portfolio. BD retains adjacent injection and drug delivery businesses and continues to operate in the insulin delivery consumables category, making it the closest historical and product-line peer.
Emerging players
- B. Braun: German medical device and infusion technology company with pen needles, syringes, and infusion sets overlapping Embecta's product portfolio. An emerging direct competitor in selected diabetes consumables and adjacent injection segments.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights6 records
Customer concentration
Embecta social profiles
Digital presenceEmbecta financial estimates
Financial estimateRevenue estimate
Valuation estimate
Embecta leadership team
Management profileNumber of profiles
Profiles4 records
Embecta subsidiaries and ownership
Company hierarchySubsidiaries2 records
Embecta funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Embecta M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Embecta
What does Embecta do?
Embecta manufactures and commercializes physical medical devices for insulin delivery, headlined by its Nano and Ultra-Fine pen needles and Ultra-Fine insulin syringes, along with injection accessories such as alcohol swabs. Following the May 2026 acquisition of Owen Mumford, the portfolio expanded to include the Aidaptus auto-injector platform for chronic care applications, and a distribution partnership added NanoSALV catalytic wound care gel in Canada. Products reach more than 30 million people across 100+ countries via healthcare providers, pharmacies, distributors, and an owned e-commerce storefront.
Is Embecta a public or private company?
Embecta is a public company. It is classified as public and is currently operating.
When was Embecta founded?
Embecta was founded in 2022. It employs 1,001 to 5,000 people.
Where is Embecta based?
Embecta is headquartered in Franklin Lakes, United States, in the North America region.
How does Embecta make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are drug Delivery Technology.
Who are Embecta's main competitors?
Broad incumbents on record are Medtronic (Diabetes division) and Novo Nordisk. Direct peers are Ypsomed, Stevanato Group, West Pharmaceutical Services, Tandem Diabetes Care, SHL Medical, Insulet and Becton Dickinson (BD). B. Braun is listed as an emerging player.
Does Embecta have an API?
No public API is recorded for Embecta.
What industry is Embecta in?
Embecta's product category is Diabetes Care Medical Devices. Its primary akta.pro industry code is HLAHAHAE, Insulin Pen Needles, Syringes & Infusion Sets (Consumables), with a secondary code of HLAHAIAC, Pen Injectors (Insulin/GLP-1/Other Pens). Its NAICS code is 339113 and its SIC code is 3841.